Mitoxantrone Completed Phase 2 / 3 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT01204710A Study of Olaratumab (IMC-3G3) in Prostate Cancer
NCT00327340Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
NCT00005847Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00124566Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
NCT00627354Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00683475A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
NCT00182741Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
NCT00017563Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer